| scholarly article | Q13442814 |
| P2093 | author name string | Cynthia Villarreal-Garza | |
| Enrique Bargalló-Rocha | |||
| Enrique Estrada-Lobato | |||
| Irma Soldevilla-Gallardo | |||
| Claudia Hs Caro-Sánchez | |||
| Rodrigo Hernández-Ramírez | |||
| Sevastian S Medina-Ornelas | |||
| P2860 | cites work | Cancer Hallmarks, Biomarkers and Breast Cancer Molecular Subtypes | Q26743510 |
| Positron Emission Tomography in Breast Cancer | Q26768486 | ||
| Dosage optimization in positron emission tomography: state-of-the-art methods and future prospects | Q26778452 | ||
| Neoadjuvant therapy in the treatment of breast cancer | Q27694514 | ||
| Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development | Q28245741 | ||
| Correlation of PUV and SUV in the extremities while using PEM as a high-resolution positron emission scanner | Q33863472 | ||
| Biological subtypes of breast cancer: Prognostic and therapeutic implications | Q34023695 | ||
| Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment | Q34074094 | ||
| Clinical utility of positron emission mammography. | Q34354581 | ||
| Positron emission mammography in breast cancer presurgical planning: comparisons with magnetic resonance imaging | Q34420301 | ||
| Molecular imaging in cancer | Q34530970 | ||
| Metabolic positron emission tomography imaging in cancer detection and therapy response | Q34786518 | ||
| Update on locally advanced breast cancer | Q35600951 | ||
| Current definition of locally advanced breast cancer | Q36169951 | ||
| Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657. | Q36212421 | ||
| Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients | Q36609527 | ||
| Partial-volume effect in PET tumor imaging | Q36823223 | ||
| Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry | Q36892788 | ||
| Body size and risk of luminal, HER2-overexpressing, and triple-negative breast cancer in postmenopausal women | Q36922387 | ||
| FDG PET, PET/CT, and breast cancer imaging | Q37052426 | ||
| Positron emission mammography (PEM): reviewing standardized semiquantitative method | Q37314333 | ||
| Assessing tumor response to therapy | Q37452321 | ||
| Ki-67 as a controversial predictive and prognostic marker in breast cancer patients treated with neoadjuvant chemotherapy | Q37658237 | ||
| Current and emerging biomarkers in breast cancer: prognosis and prediction | Q37774486 | ||
| Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parall | Q43180234 | ||
| Equivalence tests for comparing correlation and regression coefficients. | Q43567517 | ||
| Ki67 measured after neoadjuvant chemotherapy for primary breast cancer | Q44258071 | ||
| A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival | Q44682357 | ||
| Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment | Q44780586 | ||
| Prognostic impact of 18F-FDG PET/CT staging and of pathological response to neoadjuvant chemotherapy in triple-negative breast cancer. | Q48444536 | ||
| Positron emission mammography: correlation of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 status and 18F-FDG. | Q54572188 | ||
| Changes in 18F-FDG tumor metabolism after a first course of neoadjuvant chemotherapy in breast cancer: influence of tumor subtypes | Q83880963 | ||
| P433 | issue | 5 | |
| P921 | main subject | mammography | Q324634 |
| P304 | page(s) | 341-350 | |
| P577 | publication date | 2018-10-20 | |
| P1433 | published in | American journal of nuclear medicine and molecular imaging | Q27723780 |
| P1476 | title | Usefulness of positron emission mammography in the evaluation of response to neoadjuvant chemotherapy in patients with breast cancer | |
| P478 | volume | 8 |
| Q92988200 | Pre-treatment systemic immune-inflammation index is a useful prognostic indicator in patients with breast cancer undergoing neoadjuvant chemotherapy | cites work | P2860 |
Search more.